Loading clinical trials...
Loading clinical trials...
HER2 gene amplification, detected in 20% to 30% of breast cancers, was a poor prognostic factor before the advent of anti-HER2 therapies. In the early 2000s, trastuzumab revolutionised the management ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Center Eugene Marquis
NCT06949410 · Breast Cancer, HER2-positive Breast Cancer
NCT06253871 · HER2 Mutation-Related Tumors, HER2, and more
NCT04030507 · Breast Cancer, HER2-positive Breast Cancer, and more
NCT04886531 · Breast Cancer, HER2-positive Breast Cancer, and more
NCT07102381 · HER2-positive Breast Cancer, Breast Cancer
Centre de lutte contre le cancer Eugène Marquis
Rennes
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions